Nebido (testosterone undecanoate depot injection) / Bayer, Grunenthal - LARVOL DELTA

Effects of testosterone undecanoate as add-on therapy in obese hypogonadal men that are late responders to tirzepatide: a pilot study. (PubMed, Minerva Endocrinol (Torino)) - "Our preliminary findings suggest that adding TRT to tirzepatide in late tirzepatide responders who are hypogonadal may optimize weight loss quality, prevent muscle depletion, and restore sexual and metabolic health. This dual pharmacological approach represents a promising precision medicine strategy for managing complex phenotypes of male obesity-associated hypogonadism."

Journal • Endocrine Disorders • Genetic Disorders • Obesity • Sarcopenia

Simple and sensitive cellulose paper-based microextraction of 25 steroid esters from human serum/plasma for doping control purposes. (PubMed, Anal Bioanal Chem) - "The analytical workflow was qualitatively validated according to the UNI CEI EN ISO/IEC 17025 standard and the WADA technical rules and notes in terms of selectivity (target analytes were distinguishable from the matrix interferences), sensitivity (limits of detection in the range of 0.05-0.70 ng/mL), carry-over (no signals were detected in the negative sample injected after the positive sample), intra and inter-day stability of the retention times (≤0.5%), matrix effect (13-32%), extract stability (the target analytes were stable for at least 72 h in the autosampler at 10 °C), and extraction yield (43-88%). Plasma samples collected after testosterone undecanoate injection were finally analyzed: the compound was detectable in all three volunteers evaluated for at least 1 month after administration, demonstrating the effectiveness of the newly developed method for doping control purposes."

Journal

Does Human Skeletal Muscle Possess an Epigenetic Memory of Testosterone? (clinicaltrials.gov) - P2/3 | N=45 | Completed | Sponsor: Norwegian School of Sport Sciences | Recruiting ➔ Completed | Trial completion date: Sep 2025 ➔ Feb 2026 | Trial primary completion date: Jul 2025 ➔ Dec 2025

Trial completion • Trial completion date • Trial primary completion date • Sarcopenia

Easing the burden: exploring the role of long-acting testosterone formulations in gender-affirming care. (PubMed, Front Public Health) - "Although not FDA approved in the United States for gender dysphoria, testosterone undecanoate is a long-acting testosterone formulation administered every 10 weeks...Although there are no official guidelines recommending short versus long-acting testosterone use, having the availability of long-acting formulations may create space for shared decision-making between patients and providers to best address gender-affirming goals of patients. Barriers may exist in terms of paying for and acquiring long-acting formulations, making a dedicated pharmacy technician or insurance authorization specialist a critical part of a gender health program."

Journal • CNS Disorders

From venipuncture to self-sampling dried blood spots: a shift in monitoring testosterone levels. (PubMed, Clin Chem Lab Med) - "At-home DBS sampling is a feasible and reliable method for monitoring testosterone in patients treated with intramuscular testosterone undecanoate, improving patient comfort and convenience. However, DBS sampling at-home is currently unsuitable for patients using testosterone gel, likely due to contamination issues. Comprehensive patient education on collection of DBS samples is crucial to ensure high-quality DBS and accurate testosterone quantification."

Journal

Cost-Utility of Intramuscular Testosterone for Men and Male Adolescents With Organic Hypogonadotropic Hypogonadism in Brazil (ISPOR-EU 2025) - "For adults, the ICERs for the three approved formulations were: R$ 4,044.41/QALY for testosterone blend (decanoate, phenylpropionate, isocaproate, propionate); R$ 9,146.67/QALY for testosterone cypionate; R$ 5,201.39/QALY for testosterone undecanoate. Our results show that TRT is cost-effective for the management of OHH, supporting their inclusion in the minimum benefit list of Brazilian SUS."

HEOR • Endocrine Disorders

Efficacy and Safety of Recombinant Human Erythropoietin Combined with All-Trans Retinoic Acid and Testosterone Undecanoate in Treating Anemia in Patients with Lower-Risk Myelodysplastic Syndromes: A Prospective, Multicenter, Double-Blind, Randomized Controlled Clinical Study (ChiCTR) - P=N/A | N=96 | Not yet recruiting | Sponsor: The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University

New trial • Anemia • Hematological Disorders • Hematological Malignancies • Myelodysplastic Syndrome • Oncology • ASXL1 • SF3B1

Evaluation of endogenous steroid sulfates and glucuronides in urine after oral and transdermal administration of testosterone. Part I: male participants. (PubMed, J Steroid Biochem Mol Biol) - "Sulfate ratios indicated higher sensitivity to multiple administrations of testosterone undecanoate (TU) tablets and T gel, significantly prolonging detection times compared to conventional steroid profile biomarkers...These findings provide further evidence that incorporating sulfate EAAS metabolites into steroid profiling enhances detection capabilities. For advanced T doping detection, sulfate metabolites should be considered essential biomarkers in the steroid profile."

Journal

An 8-Week Virtual Exercise Environment Intervention for People Post-Stroke: A Longitudinal Mixed Methods Single Case Study. (PubMed, Inquiry) - "The device, environment, and intervention were rated as usable, and the participant attributed several functional improvements with his paretic arm to the program. The AVEED, combined with an exergaming platform, was successful in improving the cycling speed and paretic arm contribution of an individual post-stroke through an 8-week non-immersive virtual exercise environment program."

Journal • Cardiovascular

TOTEM-RRMS: TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: University Hospital, Strasbourg, France | Trial completion date: Jan 2027 ➔ Dec 2027 | Trial primary completion date: Jan 2027 ➔ Dec 2027

Trial completion date • Trial primary completion date • CNS Disorders • Multiple Sclerosis

Recognition, prevalence and prevention of falsely high serum testosterone concentrations in testosterone gel users. (PubMed, Clin Chim Acta) - "Testosterone contamination of blood samples is rather common among testosterone gel users, and can be recognized by an increased T/E ratio. To prevent testosterone contamination, application of testosterone gel especially at the venipuncture site should be avoided. Clinicians and laboratory specialists should stay attentive to this common form of contamination and instruct patients accordingly."

Journal

From venipuncture to self-sampling DBS: a shift in monitoring testosterone levels (ESPE-ESE 2025) - "For patients receiving trt via deeply intramuscular testosteroneundecanoate injection, monitoring testosterone levels via DBS sampling at home is feasible, enhancing patient comfort and convenience. Patient education is needed to ensure proper collection of DBS samples, leading to high quality DBS and accurate testosterone quantification."

Cardiovascular

Self-injection experiences among transgender people on injectable gender-affirming hormone therapy: a narrative review. (PubMed, J Am Pharm Assoc (2003)) - "Based on the types of injection-related challenges identified, pharmacists, as one of the most accessible health care providers in the United States, are well-positioned to intervene and improve the experience of patients using injectable GAHT."

Journal • Review • Pain

Exercise Heart Rate Variability Suggests Parasympathetic Hyperactivity during Simulated Military Operations Irrespective of Testosterone Administration. (PubMed, Med Sci Sports Exerc) - "Exercise HRV metrics suggested parasympathetic hyperactivity despite concomitant increases in stress across the extended simulated military operations. A single dose of testosterone undecanoate does not appear to negatively affect the autonomic response to high stress in young health physically active males."

Journal

Long-term testosterone therapy in obese men with functional hypogonadism is associated with improved urinary function and quality of life (AUA 2025) - "We compared LUTS and quality of life (QoL) in men with functional hypogonadism and obesity treated with testosterone undecanoate (TU) vs an untreated control group, patient entry start: >16 years ago... In this study long-term TTh in men with functional hypogonadism and obesity improved urinary function and QoL (measured by AMS), while in the untreated group, urinary function and QoL worsened vs baseline. Due to the observational design, findings have to be interpreted with caution."

HEOR • Endocrine Disorders • Genetic Disorders • Obesity

Testosterone Replacement in Male Cancer Survivors with Fatigue and Low Testosterone (clinicaltrials.gov) - P2 | N=240 | Recruiting | Sponsor: Seattle Institute for Biomedical and Clinical Research | Trial completion date: Jan 2026 ➔ Jan 2027 | Trial primary completion date: Jan 2026 ➔ Jan 2027

Trial completion date • Trial primary completion date • Endocrine Disorders • Fatigue • Oncology

In brief: Azmiro - a single-dose injectable formulation of testosterone cypionate. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal

A Randomized Controlled Trial Comparing Testosterone Enanthate and Testosterone Undecanoate as a Gender Affirming Hormonal Therapy in Trans Males. (PubMed, Clin Endocrinol (Oxf)) - "Both TE and TU is safe, effective and well tolerated GAHT among FtM transsexuals with no significant differences in clinical, biochemical and hormonal parameters. Testosterone undecanoate was preferred at the end of 1 year due to its long dosing intervals."

Journal • CNS Disorders • Hematological Disorders

Testosterone Treatment and Sexual Function in Men: Secondary Analysis of the T4DM (Testosterone for Diabetes) Trial. (PubMed, J Clin Endocrinol Metab) - "Testosterone treatment enhanced sexual desire and, to a lesser extent, erectile function, particularly in older men and those with higher waist circumference or depressive symptoms. Reduced waist circumference and depression independently improved sexual function."

Journal • CNS Disorders • Depression • Diabetes • Genetic Disorders • Metabolic Disorders • Psychiatry • Type 2 Diabetes Mellitus

T esters: Comparing Direct and Indirect Detection Methods of Multiple Routes of Testosterone Administration (clinicaltrials.gov) - P1 | N=14 | Completed | Sponsor: Sports Medicine Research and Testing Laboratory | Enrolling by invitation ➔ Completed | Trial completion date: Aug 2024 ➔ Nov 2024 | Initiation date: May 2024 ➔ Nov 2024 | Trial primary completion date: Aug 2024 ➔ Nov 2024

Trial completion • Trial completion date • Trial initiation date • Trial primary completion date

Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism. (PubMed, Diabetes Obes Metab) - P3 | "Semaglutide markedly improved sperm morphology, total testosterone levels and symptoms of hypogonadism. These findings highlight semaglutide's potential as a therapeutic approach for men with obesity-related FH who desire fertility."

Journal • Diabetes • Endocrine Disorders • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Does Human Skeletal Muscle Possess an Epigenetic Memory of Testosterone? (clinicaltrials.gov) - P2/3 | N=40 | Recruiting | Sponsor: Norwegian School of Sport Sciences | Not yet recruiting ➔ Recruiting

Enrollment open • Sarcopenia

Testosterone and resistance training improved physical performance and reduced fatigue in frail older men: 1 year follow-up of a randomized clinical trial. (PubMed, Aging Male) - P2/3 | "To improve health conditions among hypogonadal men ≥70 years of age using testosterone undecanoate (TU) injections, progressive strength training, and oral supplements of vitamin D, calcium, and protein...Compared to controls, only the Combo group experienced reduced fatigue and tiredness (p < 0.05). Fifty-two weeks of testosterone supplementation combined with progressive resistance training may enhance physical performance, alleviate fatigue, and had no notable detrimental impacts among males aged ≥70 suffering from mobility issues and testosterone insufficiency.Trial registration - Clinical Trials NCT02873559."

Clinical • Journal • Fatigue • Geriatric Disorders

Androgen-Induced, β-Catenin-Activated Hepatocellular Adenomatosis with Spontaneous External Rupture. (PubMed, Diagnostics (Basel)) - "He used Aveed (testosterone undecanoate injection) from age 17 and completely stopped one year before his presentation...Compared to normal hepatocytes from control tissue, the tumor cells were positive for nuclear AR (androgen receptor) expression but had no increased EZH2 (Enhancer of Zeste 2 Polycomb Repressive Complex 2 Subunit) protein expression. The case indicated that androgen-induced hepatocellular neoplasms should be included in the differential diagnosis of acute abdomen."

Journal • Fatigue • Gastrointestinal Cancer • Hematological Disorders • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Pain • Solid Tumor • AR • EZH2

Beneficial effects of exercise, testosterone, vitamin D, calcium and protein in older men-A randomized clinical trial. (PubMed, J Cachexia Sarcopenia Muscle) - "In men ≥70 years old with low-normal to low testosterone and mobility problems, supplements of testosterone, calcium, vitamin D and protein combined with progressive resistance training improved 30-s chair stand test performance, muscle strength and quality of life. Both tiredness and leg fat were reduced, and RR interval variability was increased. Significant adverse effects were not observed."

Clinical • Journal • Geriatric Disorders